<think>

The user wants me to create a Chinese title and summary for a biomedical research article about lean MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease). Let me analyze the content: Original title: "Histologic Features and Clinical Outcomes of Lean Metabolic Dysfunction-Associated Steatotic Liver Disease." This is already a clear descriptive title. I need to translate it to Chinese while keeping it self-contained. Key findings from the article: 1. Multinational retrospective study from the Global MASLD project across 41 countries 2. 18,326 adults with biopsy-confirmed MASLD 3. 6.7% were lean by BMI; 6.0% were lean by waist circumference 4. Lean MASLD most prevalent in Asia (11.3% by BMI) 5. Lean MASLD had milder histologic disease (lower advanced fibrosis prevalence, lower NAFLD activity scores) 6. Lean status was NOT independently associated with all-cause mortality or clinical events 7. Advanced fibrosis (F3-F4) WAS associated with worse outcomes (aHR 2.10 for mortality, 3.41 for clinical events) 8. FIB-4 had lower accuracy in lean vs overweight/obese (AUC 0.76 vs 0.79) 9. LSM had higher accuracy in lean vs overweight/obese (AUC 0.87 vs 0.83) Now let me write the title and summary: Title: The original title is "Histologic Features and Clinical Outcomes of Lean Metabolic Dysfunction-Associated Steatotic Liver Disease." - This is a descriptive research title. Translation: "瘦型代谢功能障碍相关脂肪性肝病（Lean MASLD）的组织学特征与临床结局" Should I keep MASLD in English? Yes, per the rules - 2-6 letter all-caps abbreviations should remain in English. Title: "瘦型代谢功能障碍相关脂肪性肝病（Lean MASLD）的组织学特征与临床结局" Summary (80-160 characters, max 3 sentences): - 18,326 patients from 41 countries - 6.7% lean by BMI, most prevalent in Asia (11.3%) - Lean MASLD had milder histologic disease but similar clinical outcomes - Advanced fibrosis, not body composition, predicted prognosis - LSM outperformed FIB-4 in lean individuals Let me draft: "全球 MASLD 项目纳入 41 国 18,326 例活检确诊 MASLD 患者，6.7% 为瘦型（BMI 定义），亚洲占比最高（11.3%）。瘦型 MASLD 肝纤维化与疾病活动度较轻，但全因死亡与临床事件风险与超重/肥胖型相当；晚期纤维化（F3-F4）才是预后的独立预测因素（死亡 aHR 2.10，临床事件 aHR 3.41），且 LSM 对瘦型患者预测准确性优于 FIB-4（AUC 0.87 vs 0.76）。" Let me count: that's about 180 characters, too long. Let me trim. "全球 MASLD 项目纳入 41 国 18,326 例活检确诊患者，6.7% 为瘦型（BMI 定义），亚洲占比最高（11.3%）。瘦型 MASLD 肝纤维化与活动度较轻，但全因死亡及临床事件风险与超重/肥胖型相当；晚期纤维化（F3-F4）才是预后的独立预测因素（全因死亡 aHR 2.10，临床事件 aHR 3.41），且 LSM 对瘦型患者的预测准确性优于 FIB-4（AUC 0.87 vs 0.76）。" Count: ~170 characters. Still a bit long. Let me trim more. Actually, let me recount more carefully: "全球 MASLD 项目纳入 41 国 18 326 例活检确诊患者，6.7% 为瘦型（BMI 定义），亚洲占比最高（11.3%）。瘦型 MASLD 肝纤维化与活动度较轻，但全因死亡及临床事件风险与超重/肥胖型相当；晚期纤维化（F3-F4）为预后独立预测因素（全因死亡 aHR 2.10，临床事件 aHR 3.41），且 LSM 对瘦型患者的预测准确性优于 FIB-4（AUC 0.87 vs 0.76）。" Let me count Chinese characters and numbers: 全球MASLD项目纳入41国18326例活检确诊患者，6.7%为瘦型（BMI定义），亚洲占比最高（11.3%）。瘦型MASLD肝纤维化与活动度较轻，但全因死亡及临床事件风险与超重/肥胖型相当；晚期纤维化（F3-F4）为预后独立预测因素（全因死亡aHR 2.10，临床事件aHR 3.41），且LSM对瘦型患者的预测准确性优于FIB-4（AUC 0.87 vs 0.76）。 Counting Chinese characters (not counting English/numbers/punctuation): 全球MASLD项目纳入国例活检确诊患者为瘦型BMI定义亚洲占比最高瘦型MASLD肝纤维化与活动度较轻但全因死亡及临床事件风险与超重肥胖型相当晚期纤维化为预后独立预测因素全因死亡临床事件且对瘦型患者的预测准确性优于 = 让我数一下 全球(2) MASLD(5)项目(2)纳入(2) 41(2) 国(1) 18326(5) 例(1)活检(2)确诊(2)患者(2)，6.7%(4) 为(1)瘦型(2)（BMI(3)定义(2)），亚洲(2)占比(2)最高(2)（11.3%(6)）。瘦型MASLD(8)肝(1)纤维化(3)与(1)活动度(3)较轻(2)，但(1)全因(2)死亡(2)及(1)临床(2)事件(2)风险(2)与(1)超重(2)/肥胖(2)型(1)相当(2)；晚期(2)纤维化(3)（F3-F4(5)）为(1)预后(2)独立(2)预测(2)因素(2)（全因(2)死亡(2) aHR(3) 2.10(4)，临床(2)事件(2) aHR(3) 3.41(4)），且(1) LSM(3) 对(1)瘦型(2)患者(2)的(1)预测(2)准确性(3)优于(2) FIB-4(5)（AUC(3) 0.87(4) vs(2) 0.76(4)）。 That's a lot of characters total including English/numbers. Let me estimate: roughly 180-190 total characters. Need to trim. Let me focus on the most important points and make it tighter: "全球 MASLD 项目纳入 41 国 18,326 例活检确诊患者，6.7% 为瘦型（BMI 定义），亚洲占比最高（11.3%）。瘦型 MASLD 肝纤维化与活动度较轻，全因死亡与临床事件风险与超重/肥胖型相当；晚期纤维化（F3-F4）才是预后独立预测因素（全因死亡 aHR 2.10，临床事件 aHR 3.41），且 LSM 对瘦型患者预测准确性优于 FIB-4（AUC 0.87 vs 0.76）。" This should be around 160 characters. Let me be more precise. Counting all characters including English numbers and punctuation: "全球 MASLD 项目纳入 41 国 18,326 例活检确诊患者，6.7% 为瘦型（BMI 定义），亚洲占比最高（11.3%）。瘦型 MASLD 肝纤维化与活动度较轻，全因死亡与临床事件风险与超重/肥胖型相当；晚期纤维化（F3-F4）才是预后独立预测因素（全因死亡 aHR 2.10，临床事件 aHR 3.41），且 LSM 对瘦型患者预测准确性优于 FIB-4（AUC 0.87 vs 0.76）。" This is approximately 160 characters including all content. That fits. Actually, the rule says "80-160字" - this is about Chinese characters. Let me see. In Chinese biomedical writing, numbers and English words might or might not be counted. Let me assume the rule means total length including all visible characters should be 80-160. Let me count again more carefully character by character: 全(1)球(2) (3)M(4)A(5)S(6)L(7)D(8) (9)项(10)目(11)纳(12)入(13) (14)4(15)1(16) (17)国(18)1(19)8(20),(21)3(22)2(23)6(24) (25)例(26)活(27)检(28)确(29)诊(30)患(31)者(32)，(33)6(34).(35)7(36)%(37) (38)为(39)瘦(40)型(41)（(42)B(43)M(44)I(45) (46)定(47)义(48)）(49)，(50)亚(51)洲(52)占(53)比(54)最(55)高(56)（(57)1(58)1(59).(60)3(61)%(62)）(63)。(64)瘦(65)型(66) (67)M(68)A(69)S(70)L(71)D(72) (73)肝(74)纤(75)维(76)化(77)与(78)活(79)动(80)度(81)较(82)轻(83)，(84)全(85)因(86)死(87)亡(88)与(89)临(90)床(91)事(92)件(93)风(94)险(95)与(96)超(97)重(98)/(99)肥(100)胖(101)型(102)相(103)当(104)；(105)晚(106)期(107)纤(108)维(109)化(110)（(111)F(112)3(113)-(114)F(115)4(116)）(117)才(118)是(119)预(120)后(121)独(122)立(123)预(124)测(125)因(126)素(127)（(128)全(129)因(130)死(131)亡(132) (133)a(134)H(135)R(136) (137)2(138).(139)1(140)0(141)，(142)临(143)床(144)事(145)件(146) (147)a(148)H(149)R(150) (151)3(152).(153)4(154)1(155)）(156)，(157)且(158) (159)L(160)S(161)M(162) (163)对(164)瘦(165)型(166)患(167)者(168)预(169)测(170)准(171)确(172)性(173)优(174)于(175) (176)F(177)I(178)B(179)-(180)4(181)（(182)A(183)U(184)C(185) (186)0(187).(188)8(189)7(190) (191)v(192)s(193) (194)0(195).(196)7(197)6(198)）(199)。(200) That's about 200 characters. Too long. Let me trim. Let me make it more concise: "全球 MASLD 项目纳入 41 国 18,326 例活检确诊患者，其中 6.7% 为瘦型，亚洲占比最高（11.3%）。瘦型 MASLD 肝纤维化与疾病活动度较轻，全因死亡及临床事件风险与超重/肥胖型相当；晚期纤维化（F3-F4）才是预后独立预测因素（aHR 分别为 2.10 和 3.41），且 LSM 对瘦型患者准确性优于 FIB-4（AUC 0.87 vs 0.76）。" Let me count this... approximately 165 characters. Still slightly over. Try again: "全球 MASLD 项目纳入 41 国 18,326 例活检确诊 MASLD 患者，6.7% 为瘦型（BMI 定义），亚洲占比最高（11.3%）。瘦型 MASLD 组织学表现较轻，全因死亡及临床事件风险与超重/肥胖型相当；晚期纤维化（F3-F4）为预后独立预测因素，且 LSM 对瘦型患者准确性优于 FIB-4（AUC 0.87 vs 0.76）。" Hmm, this drops the HR values. Let me see if I can fit them. "全球 MASLD 项目纳入 41 国 18,326 例活检确诊患者，6.7% 为瘦型（BMI 定义），亚洲占比最高（11.3%）。瘦型 MASLD 纤维化与活动度较轻，全因死亡与临床事件风险与超重/肥胖型相当；晚期纤维化（F3-F4）是预后独立预测因素（aHR 2.10 与 3.41），且 LSM 对瘦型患者准确性优于 FIB-4（AUC 0.87 vs 0.76）。" Let me count: about 170 characters. Need to cut more. "41 国 18,326 例活检确诊 MASLD 中 6.7% 为瘦型，亚洲占比最高（11.3%）。瘦型 MASLD 纤维化与活动度较轻，全因死亡与临床事件风险与超重/肥胖型相当；晚期纤维化（F3-F4）才是预后独立预测因素（aHR 2.10 和 3.41），且 LSM 对瘦型患者准确性优于 FIB-4（AUC 0.87 vs 0.76）。" Count: ~150. This works. Actually let me re-read the requirements: - 80-160 字 - 最多 3 句 - 直接说内容本身 The first sentence should be the main finding/answer (30-70 characters). Then 1-2 more supporting facts. My first sentence: "41 国 18,326 例活检确诊 MASLD 中 6.7% 为瘦型，亚洲占比最高（11.3%）。" - This is descriptive but maybe not the key answer. Actually, the key finding per the paper's conclusion is: "Lean MASLD represents a distinct phenotype with milder histologic disease but similar clinical outcomes compared with overweight/obese MASLD. Fibrosis severity, rather than body composition, was associated with prognosis." So the first answer sentence should focus on this. Let me restructure: "全球 MASLD 项目纳入 41 国 18,326 例活检确诊患者，发现瘦型 MASLD 组织学表现较轻但临床结局与超重/肥胖型相当；6.7% 为瘦型，亚洲占比最高（11.3%）。晚期纤维化（F3-F4）才是预后独立预测因素（全因死亡 aHR 2.10，临床事件 aHR 3.41），且 LSM 对瘦型患者准确性优于 FIB-4（AUC 0.87 vs 0.76）。" Count: about 165. Let me see if I can compress more. Try: "全球 MASLD 项目纳入 41 国 18,326 例活检确诊患者，发现瘦型 MASLD 组织学较轻但临床结局与超重/肥胖型相似；6.7% 为瘦型，亚洲占比最高（11.3%）。晚期纤维化（F3-F4）才是预后独立预测因素（死亡 aHR 2.10、临床事件 3.41），且 LSM 对瘦型准确性优于 FIB-4（AUC 0.87 vs 0.76）。" Count: ~155. Better. Actually let me just count carefully: 全(1)球(2) (3)M(4)A(5)S(6)L(7)D(8) (9)项(10)目(11)纳(12)入(13) (14)4(15)1(16) (17)国(18)1(19)8(20),(21)3(22)2(23)6(24) (25)例(26)活(27)检(28)确(29)诊(30)患(31)者(32)，(33)发(34)现(35)瘦(36)型(37) (38)M(39)A(40)S(41)L(42)D(43) (44)组(45)织(46)学(47)较(48)轻(49)但(50)临(51)床(52)结(53)局(54)与(55)超(56)重(57)/(58)肥(59)胖(60)型(61)相(62)似(63)；(64)6(65).(66)7(67)%(68) (69)为(70)瘦(71)型(72)，(73)亚(74)洲(75)占(76)比(77)最(78)高(79)（(80)1(81)1(82).(83)3(84)%(85)）(86)。(87)晚(88)期(89)纤(90)维(91)化(92)（(93)F(94)3(95)-(96)F(97)4(98)）(99)才(100)是(101)预(102)后(103)独(104)立(105)预(106)测(107)因(108)素(109)（(110)死(111)亡(112) (113)a(114)H(115)R(116) (117)2(118).(119)1(120)0(121)、(122)临(123)床(124)事(125)件(126) (127)3(128).(129)4(130)1(131)）(132)，(133)且(134) (135)L(136)S(137)M(138) (139)对(140)瘦(141)型(142)准(143)确(144)性(145)优(146)于(147) (148)F(149)I(150)B(151)-( </think>